Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to68Ga-DOTATATE/-TOC uptake

68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?

(2016) Michael Sommerauer et al.   NEURO-ONCOLOGY

90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas

(2015) K. Gerster-Gillieron et al.   JOURNAL OF NUCLEAR MEDICINE

Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue

(2015) W. Rachinger et al.   JOURNAL OF NUCLEAR MEDICINE

Somatostatin Receptor-Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

(2015) N. Marincek et al.   JOURNAL OF NUCLEAR MEDICINE

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

(2015) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Peptide Receptor Radionuclide Therapy in Patients with Inoperable Meningiomas: Our Experience and Review of the Literature

(2014) Fabio Minutoli et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy

(2014) Marta Simó et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review

(2014) T. Kaley et al.   NEURO-ONCOLOGY

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

(2014) Thomas J. Kaley et al.   NEURO-ONCOLOGY

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

(2014) A. D. Norden et al.   NEUROLOGY

PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma

(2012) Heribert Hänscheid et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

(2012) Linda Villard et al.   JOURNAL OF CLINICAL ONCOLOGY

Atypical and anaplastic meningiomas treated with bevacizumab

(2012) Lakshmi Nayak et al.   JOURNAL OF NEURO-ONCOLOGY

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

(2009) Mirco Bartolomei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

(2009) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY